Review paper
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Abstract
Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the majority of patients have primary or acquired resistance to these immunotherapies. There is a significant unmet need for predictive biomarkers that can reliably identify patients who derive a clinically meaningful response from PD-1/PD-L1 blockade. High tumor mutational...
Paper Details
Title
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Published Date
Mar 1, 2021
Journal
Volume
27
Issue
5
Pages
1236 - 1241
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History